Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3636-3654

  Griffin, Latoya ^a   Annaert, Pieter ^b   Brouwer, Kim L R ^a  

^a University of North Carolina   (United States)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

ABC transporters; ADME; Drug transport; HIV AIDS; Organic anion transporting polypeptide transporters; Pharmacokinetics pharmacodynamics

Indexed keywords

ATAZANAVIR; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A4; DARUNAVIR; DELAVIRDINE; DIGOXIN; ELVUCITABINE; FEXOFENADINE; FOSAMPRENAVIR; GLYCOPROTEIN P; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; KETOCONAZOLE; LOPERAMIDE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; NELFINAVIR; ORGANIC CATION TRANSPORTER; RAPAMYCIN; RITONAVIR; SAQUINAVIR; SILDENAFIL; TACROLIMUS; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG;

DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INHIBITION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; REVIEW; SINGLE DRUG DOSE;

EID: 79960133743     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22655     Document Type: Review

References (170)

1. Bragman K. 1996. Saquinavir: An HIV protease inhibitor. Adv Exp Med Biol 394:305-317.
2. Anonymous. 2011. Antiretroviral drugs used in the treatment of HIV infection. Last Accessed May 10, 2011.
3. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. 2010. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304(3):321-333.
4. Bierman W, van Agtmael M, Nijhuis M, Danner S, Boucher C. 2009. HIV monotherapy with ritonavir-boosted protease inhibitors: A systematic review. AIDS 23(3):279-291.
5. Busse K, Penzak S. 2007. Darunavir: A second-generation protease inhibitor. Am J Health Syst Pharm 64(15):1593-1602.
6. Hull M, Montaner J. 2011. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med. (in press
7. Josephson F. 2010. Drug-drug interactions in the treatment of HIV infection: Focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med 268(6):530-539.
8. Moyle G, Back D. 2001. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2(2):105-113.
9. Youle M. 2007. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 60(6):1195-1205.
10. McComsey G, Rightmire A, Wirtz V, Yang R, Mathew M, McGrath D. 2009. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: A 96-week randomized, controlled study. Clin Infect Dis 48(9):1323-1326.
11. Ford J, Khoo SH, Back DJ. 2004. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 54(6):982-990.
12. Kashuba A, Dyer J, Kramer L, Raasch R, Eron J, Cohen M. 1999. Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 43(8):1817-1826.
13. Williams GC, Sinko PJ. 1999. Oral absorption of the HIV protease inhibitors: A current update. Adv Drug Deliv Rev 39(1-3):211-238.
14. Kis O, Zastre JA, Ramaswamy M, Bendayan R. 2010. pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: Potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther 334(3):1009-1022.
15. Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. 2006. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J Antimicrob Chemother 58(5):1009-1016.
16. Loregian A, Pagni S, Ballarin E, Sinigalia E, Parisi S, Palu G. 2006. Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection. J Pharm Biomed Anal 42(4):500-505.
17. Lin J. 1997. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Adv Drug Deliv Rev 27(2-3):215-233.
18. Lin J, Chen I, Vastag K, Ostovic D. 1995. pH-dependent oral absorption of L-735, 524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos 23(7):730-735.
19. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet A. 2010. Intracellular Pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 49(1):17-45.
20. Longer M, Shetty B, Zamansky I, Tyle P. 1995. Preformulation studies of a novel HIV protease inhibitor, AG1343. J Pharm Sci 84(9):1090-1093.
21. Gallant JE. 2004. Protease-inhibitor boosting in the treatment-experienced patient. AIDS Rev 6(4):226-233.
22. Chaudhary M, Gupta S, Khare S, Lal S. 2010. Diagnosis of tuberculosis in an era of HIV pandemic: A review of current status and future prospects. Indian J Med Microbiol 28(4):281-289.
23. Parker AJ, Houston JB. 2008. Rate-limiting steps in hepatic drug clearance: Comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. Drug Metab Dispos 36(7):1375-1384.
24. Kis O, Robillard K, Chan GN, Bendayan R. 2010. The complexities of antiretroviral drug-drug interactions: Role of ABC and SLC transporters. Trends Pharmacol Sci 31(1):22-35.
25. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. 2000. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273(1):251-260.
26. Kim RB. 2003. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 33 (Suppl 2):1-5.
27. Su Y, Zhang X, Sinko PJ. 2004. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm 1(1):49-56.
28. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE, Gibbons S, Bray PG, Back DJ, Khoo SH, Owen A. 2010. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 20(2):112-120.
29. Janneh O, Hartkoorn R, Jones E, Owen A, Ward S, Davey R, Back D, Khoo S. 2008. Cultured CD4T cells and primary human lymphocytes express hOATPs: Intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol 155(6):875-883.
30. Annaert P, Ye ZW, Stieger B, Augustijns P. 2010. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40(3):163-176.
31. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A. 2010. ADME pharmacogenetics: Investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 20(4):217-230.
32. Zhang L, Brett CM, Giacomini KM. 1998. Role of organic cation transporters in drug absorption and elimination. Annu Rev Pharmacol Toxicol 38:431-460.
33. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, Faetkenheuer G, Taubert D. 2008. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 36(8):1616-1623.
34. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM. 2000. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos 28(3):329-334.
35. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. 2004. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1(1):27-42.
36. Weiss J, Haefeli WE. 2010. Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol 280:219-279.
37. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 55(1):3-29.
38. Park S, Sinko PJ. 2005. P-glycoprotein and multidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 312(3):1249-1256.
39. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101(2):289-294.
40. Agarwal S, Pal D, Mitra AK. 2007. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 339(1-2):139-147.
41. Konig S, Herzog M, Theile D, Zembruski N, Haefeli W, Weiss J. 2010. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 65(11):2319-2328.
42. van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, Breimer DD. 2001. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 15(4):483-491.
43. van Waterschoot R, ter Heine R, Wagenaar E, van der Kruijssen C, Rooswinkel R, Huitema A, Beijnen J, Schinkel A. 2010. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 160(5):1224-1233.
44. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37(11):3594-3601.
45. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, Hidalgo IJ, Rhodes GR, Ray AS. 2007. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 51(10):3498-3504.
46. Konig SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. 2010. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 65(11):2319-2328.
47. Bierman WF, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, Danner SA, Scheper RJ. 2010. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 65(8):1672-1680.
48. Gupta A, Zhang Y, Unadkat JD, Mao Q. 2004. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2 J Pharmacol Exp Ther 310(1):334-341.
49. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T. 2007. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59(2):238-245.
50. Ronaldson PT, Persidsky Y, Bendayan R. 2008. Regulation of ABC membrane transporters in glial cells: Relevance to the pharmacotherapy of brain HIV-1 infection. Glia 56(16):1711-1735.
51. Leslie EM, Deeley RG, Cole SP. 2005. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204(3):216-237.
52. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, Keppler D. 1997. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J 327(Pt 1):305-310.
53. Keppler D. 2011. Multidrug resistance proteins (MRPs, ABCCs): Importance for pathophysiology and drug therapy. Handb Exp Pharmacol 201:299-323.
54. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. 2002. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16(17):2295-2301.
55. Ye ZW, Camus S, Augustijns P, Annaert P. 2010. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos 31(2-3):178-188.
56. Lee LS, Soon GH, Shen P, Yong EL, Flexner C, Pham P. 2010. Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers. Antivir Ther 15(2):275-279.
57. Back DJ. 2006. Drug-drug interactions that matter. Top HIV Med 14(2):88-92.
58. Pal D, Mitra A. 2006. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 1(3):323-339.
59. Dam E, Lebel-Binay S, Rochas S, Thibaut L, Faudon J, Thomas C, Essioux L, Hill A, Schutz M, Clavel F. 2007. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir. Antivir Ther 12(3):371-380.
60. Scholler-Gyure M, Kakuda T, Sekar V, Woodfall B, De Smedt G, Lefebvre E, Peeters M, Hoetelmans R. 2007. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 12(5):789-796.
61. Kiser J, Carten M, Aquilante C, Anderson P, Wolfe P, King T, Delahunty T, Bushman L, Fletcher C. 2008. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 83(2):265-272.
62. Cihlar T, Ray A, Laflamme G, Vela J, Tong L, Fuller M, Roy A, Rhodes G. 2007. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 12(2):267-272.
63. van Heeswijk R, Bourbeau M, Campbell P, Seguin I, Chauhan B, Foster B, Cameron D. 2006. Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46(7):758-767.
64. Perloff M, von Moltke L, Greenblatt D. 2002. Fexofenadine transport in Caco-2 cells: Inhibition with verapamil and ritonavir. J Clin Pharmacol 42(11):1269-1274.
65. Fukushima K, Haraya K, Terasaka S, Ito Y, Sugioka N, Takada K. 2008. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats. Biol Pharm Bull 31(6):1209-1214.
66. Kharasch E, Bedynek P, Walker A, Whittington D, Hoffer C. 2008. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther 84(4):506-512.
67. Kharasch E, Hoffer C, Whittington D, Walker A, Bedynek P. 2009. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: Insights from methadone interactions with ritonavir/indinavir. Anesthesiology 110(3):660-672.
68. Penzak S, Shen J, Alfaro R, Remaley A, Natarajan V, Falloon J. 2004. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit 26(3):322-330.
69. Bendayan R, Lee G, Bendayan M. 2002. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 57(5):365-380.
70. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. 2004. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 76(1):73-84.
71. Dickinson L, Khoo S, Back D. 2010. Pharmacokinetics and drug-drug interactions of antiretrovirals: An update. Antiviral Res 85(1):176-189.
72. Schmitt C, Kaeser B, Riek M, Bech N, Kreuzer C. 2010. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. Int J Clin Pharmacol Ther 48(3):192-199.
73. Dumond J, Vourvahis M, Rezk N, Patterson K, Tien H, White N, Jennings S, Choi S, Li J, Wagner M, La-Beck N, Drulak M, Sabo J, Castles M, Macgregor T, Kashuba A. 2010. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 87(6):735-742.
74. Wyen C, Fuhr U, Frank D, Aarnoutse R, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner J, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schomig E, Burger D, Fatkenheuer G, Jetter A. 2008. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 84(1):75-82.
75. Mukwaya G, MacGregor T, Hoelscher D, Heming T, Legg D, Kavanaugh K, Johnson P, Sabo J, McCallister S. 2005. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 49(12):4903-4910.
76. Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, Haefeli W, Mikus G. 2001. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 70(5):405-414.
77. Justesen U, Klitgaard N, Brosen K, Pedersen C. 2003. Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 55(1):100-106.
78. Barau C, Blouin P, Creput C, Taburet A, Durrbach A, Furlan V. 2009. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. Fundam Clin Pharmacol 23(4):423-425.
79. Mertz D, Battegay M, Marzolini C, Mayr M. 2009. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. Am J Kidney Dis 54(1):e1-e4.
80. Sekar V, Lefebvre E, De Marez T, De Pauw M, De Paepe E, Vangeneugden T, Hoetelmans R. 2008. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: Phase I randomized, open-label, two-way crossover study. Clin Drug Investig 28(8):479-485.
81. Sekar V, Lefebvre E, De Pauw M, Vangeneugden T, Hoetelmans R. 2008. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Clin Pharmacol 66(2):215-221.
82. Laboratories A Norvir (ritonavir) US prescribing information. Accessed March 2, 2011, at.
83. Laboratories A Kaletra (lopinavir/ritonavir) US prescribing information. Accessed March 2, 2011, at.
84. Vertex Ga Lexiva (fosamprenavir) US prescribing information. Accessed March 2, 2011, at.
85. Pham P, la Porte C, Lee L, van Heeswijk R, Sabo J, Elgadi M, Piliero P, Barditch-Crovo P, Fuchs E, Flexner C, Cameron D. 2009. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 53(10):4385-4392.
86. Fichtenbaum C, Gerber J, Rosenkranz S, Segal Y, Aberg J, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F. 2002. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16(4):569-577.
87. Hoetelmans RMW, Lasure A, Koester A, de Pauw M, van Baelen B, Peeters M, Parys W, Lefebvre E. 2004. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, ed.
88. Huang L, Wang Y, Grimm S. 2006. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34(5):738-742.
89. Hagenbuch B, Meier P. 2003. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609(1):1-18.
90. Annaert P, Ye Z, Stieger B, Augustijns P. 2010. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40(3):163-176.
91. Matsson P, Englund G, Ahlin G, Bergstrom C, Norinder U, Artursson P. 2007. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2 J Pharmacol Exp Ther 323(1):19-30.
92. Busti A, Bain A, Hall Rn, Bedimo R, Leff R, Meek C, Mehvar R. 2008. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 51(6):605-610.
93. Watanabe T, Kusuhara H, Sugiyama Y. 2010. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn 37(6):575-590.
94. Kharasch E, Walker A, Whittington D, Hoffer C, Bedynek P. 2009. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 101(3):158-168.
95. Colucci P, Pottage J, Robison H, Turgeon J, Ducharme M. 2009. Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers. Antimicrob Agents Chemother 53(2):646-650.
96. Toy J, Giguere P, Kravcik S, la Porte C. 2011. Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia. AIDS 25(4):541-542.
97. Zembruski N, Haefeli W, Weiss J. 2011. Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother 55(3):1282-1284.
98. Kakuda T, Scholler-Gyure M, Hoetelmans R. 2010. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther 15(6):817-829.
99. McIlleron H, Meintjes G, Burman W, Maartens G. 2007. Complications of antiretroviral therapy in patients with tuberculosis: Drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196 (Suppl 1):S63-S75.
100. Brouwers J, Tack J, Lammert F, Augustijns P. 2006. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: A case study with amprenavir. J Pharm Sci 95(2):372-383.
101. Mouly SJ, Paine MF, Watkins PB. 2004. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J Pharmacol Exp Ther 308(3):941-948.
102. la Porte C, Colbers E, Bertz R, Voncken D, Wikstrom K, Boeree M, Koopmans P, Hekster Y, Burger D. 2004. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 48(5):1553-1560.
103. Mallolas J, Sarasa M, Nomdedeu M, Soriano A, Lopez-Pua Y, Blanco J, Martinez E, Gatell J. 2007. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 8(2):131-134.
104. Baciewicz A, Chrisman C, Finch C, Self T. 2008. Update on rifampin and rifabutin drug interactions. Am J Med Sci 335(2):126-136.
105. Yang X, Hu Z, Duan W, Zhu Y, Zhou S. 2006. Drug-herb interactions: Eliminating toxicity with hard drug design. Curr Pharm Des 12(35):4649-4664.
106. Holmstock N, Mols R, Annaert P, Augustijns P. 2010. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption. Drug Metab Dispos 38(9):1407-1410.
107. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H. 2009. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull 32(9):1588-1593.
108. Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron D. 2000. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 68(6):637-646.
109. Profit L, Eagling V, Back D. 1999. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13(13):1623-1627.
110. Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, Vangeneugden T, De Pauw M, Hoetelmans R. 2010. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 54(10):4440-4445.
111. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. 2005. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res 22(8):1259-1268.
112. Brown KC, Paul S, Kashuba AD. 2009. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 48(4):211-241.
113. Tirona RG, Leake BF, Wolkoff AW, Kim RB. 2003. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304(1):223-228.
114. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28(6):655-660.
115. Cook JA, Feng B, Fenner KS, Kempshall S, Liu R, Rotter C, Smith DA, Troutman MD, Ullah M, Lee CA. 2010. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm 7(2):398-411.
116. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2006. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34(7):1229-1236.
117. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. 2001. Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 134(8):1601-1608.
118. Keogh JP, Kunta JR. 2006. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 27(5):543-554.
119. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27(8):866-871.
120. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. 2010. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: Functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 298(4):F997-F1005.
121. Haslam IS, Jones K, Coleman T, Simmons NL. 2008. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84 Biochem Pharmacol 76(7):850-861.
122. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. 2005. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. Aids 19(15):1617-1625.
123. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G. 2004. Predicting P-glycoprotein effects on oral absorption: Correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res 21(5):819-826.
124. van Gelder J, Deferme S, Naesens L, De Clercq E, van den Mooter G, Kinget R, Augustijns P. 2002. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 30(8):924-930.
125. Shitara Y. 2011. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet. (in press
126. di Masi A, De Marinis E, Ascenzi P, Marino M. 2009. Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Aspects Med 30(5):297-343.
127. Meyer zu Schwabedissen H, Kim R. 2009. Hepatic OATP1B transporters and nuclear receptors PXR and CAR: Interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Mol Pharm 6(6):1644-1661.
128. Dixit V, Hariparsad N, Li F, Desai P, Thummel K, Unadkat J. 2007. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: Implications for predicting clinical drug interactions. Drug Metab Dispos 35(10):1853-1859.
129. Foisy M, Yakiwchuk E, Hughes C. 2008. Induction effects of ritonavir: Implications for drug interactions. Ann Pharmacother 42(7):1048-1059.
130. Scholler-Gyure M, Kakuda T, Raoof A, De Smedt G, Hoetelmans R. 2009. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 48(9):561-574.
131. Gupta A, Mugundu G, Desai P, Thummel K, Unadkat J. 2008. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: Studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos 36(6):1172-1180.
132. Haslam IS, Jones K, Coleman T, Simmons NL. 2008. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Br J Pharmacol 154(1):246-255.
133. Perloff E, Duan S, Skolnik P, Greenblatt D, von Moltke L. 2005. Atazanavir: Effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 33(6):764-770.
134. Zastre J, Chan G, Ronaldson P, Ramaswamy M, Couraud P, Romero I, Weksler B, Bendayan M, Bendayan R. 2009. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 87(4):1023-1036.
135. Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ. 2003. Lopinavir: Acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. Aids 17(7):1092-1094.
136. Beghin D, Forestier F, Noel-Hudson M, Gavard L, Guibourdenche J, Farinotti R, Gil S. 2010. Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir. Eur J Obstet Gynecol Reprod Biol 152(1):55-59.
137. Perloff M, Von Moltke L, Marchand J, Greenblatt D. 2001. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 90(11):1829-1837.
138. Perloff M, Stormer E, von Moltke L, Greenblatt D. 2003. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 20(8):1177-1183.
139. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier P. 2001. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69(4):223-231.
140. McRae M, Lowe C, Tian X, Bourdet D, Ho R, Leake B, Kim R, Brouwer KLR, Kashuba A. 2006. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther 318(3):1068-1075.
141. McRae M, Rezk N, Bridges A, Corbett A, Tien H, Brouwer K, Kashuba A. 2010. Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: Possible implications for hepatotoxicity. Pharmacotherapy 30(1):17-24.
142. Rotger M, Taffe P, Bleiber G, Gunthard H, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M, Telenti A. 2005. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 192(8):1381-1386.
143. Campbell SD, de Morais SM, Xu JJ. 2004. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150(2):179-187.
144. Ye ZW, Van Pelt J, Camus S, Snoeys J, Augustijns P, Annaert P. 2010. Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes. J Pharm Sci 99(6):2886-2898.
145. Richmond S, Carper M, Lei X, Zhang S, Yarasheski K, Ramanadham S. 2010. HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters. Biochim Biophys Acta 1801(5):559-566.
146. Jorajuria S, Clayette P, Dereuddre-Bosquet N, Benlhassan-Chahour K, Thiebot H, Vaslin B, Le Grand R, Dormont D. 2003. The expression of P-glycoprotein and cellular kinases is modulated at the transcriptional level by infection and highly active antiretroviral therapy in a primate model of AIDS. AIDS Res Hum Retroviruses 19(4):307-311.
147. Lucia MB, Cauda R, Landay AL, Malorni W, Donelli G, Ortona L. 1995. Transmembrane P-glycoprotein (P-gp/P-170) in HIV Infection: Analysis of Lymphocyte Surface Expression and Drug-Unrelated Function. 11(8):893-901.
148. Meaden ER, Hoggard PG, Maher B, Khoo SH, Back DJ. 2001. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses 17(14):1329-1332.
149. Lucia MB, Savarino A, Straface E, Golotta C, Rastrelli E, Matarrese P, Rutella S, Malorni W, Cauda R. 2005. Role of lymphocyte multidrug resistance protein 1 in HIV infection: Expression, function, and consequences of inhibition. J Acquir Immune Defic Syndr 40(3):257-266.
150. Andreana A, Aggarwal S, Gollapudi S, Wien D, Tsuruo T, Gupta S. 1996. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4 +and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 12(15):1457-1462.
151. Turriziani O, Gianotti N, Falasca F, Boni A, Vestri AR, Zoccoli A, Lazzarin A, Antonelli G. 2008. Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J Med Virol 80(5):766-771.
152. Denk GU, Soroka CJ, Takeyama Y, Chen WS, Schuetz JD, Boyer JL. 2004. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 40(4):585-591.
153. Gradhand U, Lang T, Schaeffeler E, Glaeser H, Tegude H, Klein K, Fritz P, Jedlitschky G, Kroemer HK, Bachmakov I, Anwald B, Kerb R, Zanger UM, Eichelbaum M, Schwab M, Fromm MF. 2008. Variability in human hepatic MRP4 expression: Influence of cholestasis and genotype. Pharmacogenomics J 8(1):42-52.
154. Ogasawara K, Terada T, Katsura T, Hatano E, Ikai I, Yamaoka Y, Inui K. 2010. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet 25(2):190-199.
155. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, Gonzalez FJ, Marschall HU, Denk H, Trauner M. 2003. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 125(3):825-838.
156. Hinoshita E, Taguchi K, Inokuchi A, Uchiumi T, Kinukawa N, Shimada M, Tsuneyoshi M, Sugimachi K, Kuwano M. 2001. Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection. J Hepatol 35(6):765-773.
157. Nakai K, Tanaka H, Hanada K, Ogata H, Suzuki F, Kumada H, Miyajima A, Ishida S, Sunouchi M, Habano W, Kamikawa Y, Kubota K, Kita J, Ozawa S, Ohno Y. 2008. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos 36(9):1786-1793.
158. Bousquet L, Roucairol C, Hembury A, Nevers MC, Creminon C, Farinotti R, Mabondzo A. 2008. Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res Hum Retroviruses 24(9):1147-1154.
159. Bossi P, Legrand O, Faussat AM, Legrand M, Bricaire F, Marie JP, Agut H, Diquet B, Katlama C, Huraux JM, Calvez V. 2003. P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors. HIV Med 4(1):67-71.
160. Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A. 2009. Combination of tenofovir and emtricitabine plus efavirenz: In vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother 53(3):896-902.
161. Janneh O, Owen A, Chandler B, Hartkoorn R, Hart C, Bray P, Ward S, Back D, Khoo S. 2005. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19(18):2097-2102.
162. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. 2001. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 276(36):33309-33312.
163. Cervia JS, Chantry CJ, Hughes MD, Alvero C, Meyer WA, 3rd, Hodge J, Borum P, Moye J, Jr., Spector SA. 2010. Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy. Pediatr Infect Dis J 29(12):1118-1122.
164. Diao L, Li N, Brayman TG, Hotz KJ, Lai Y. 2010. Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}. J Biol Chem 285(41):31185-31192.
165. Vee ML, Lecureur V, Stieger B, Fardel O. 2009. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos 37(3):685-693.
166. Brazille P, Dereuddre-Bosquet N, Leport C, Clayette P, Boyer O, Vilde JL, Dormont D, Benveniste O. 2003. Decreases in plasma TNF-alpha level and IFN-gamma mRNA level in peripheral blood mononuclear cells (PBMC) and an increase in IL-2 mRNA level in PBMC are associated with effective highly active antiretroviral therapy in HIV-infected patients. Clin Exp Immunol 131(2):304-311.
167. Coburger C, Lage H, Molnar J, Langner A, Hilgeroth A. 2010. Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors. J Pharm Pharmacol 62(12):1704-1710.
168. Shaik N, Pan G, Elmquist WF. 2008. Interactions of pluronic block copolymers on P-gp efflux activity: Experience with HIV-1 protease inhibitors. J Pharm Sci 97(12):5421-5433.
169. Golden PL, Pollack GM. 2003. Blood-brain barrier efflux transport. J Pharm Sci 92(9):1739-1753.
170. Thomas SA. 2004. Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 10(12):1313-1324.